Lazard Upgrades Valeant Pharma (VRX) to Hold
More News related to VRX
- Valeant Pharmaceuticals Highlights Taribavirin Phase IIb End of Study Data Presentation at American Association for the Study of Liver Disease (AASLD) Annual Meeting
- Valeant Pharma (VRX) Posts non-GAAP EPS of $0.58; Raises FY09 EPS Guidance
- Valeant Pharmaceuticals Reports Third Quarter Financial Results
- Valeant to Acquire Polish Products
- Valeant Pharmaceuticals to Announce 2009 Third Quarter Results on November 2, 2009
More News related to Upgrades
- S&P Revises Outlook on Sirius XM (SIRI) from Stable to Positive
- DA Davidson Upgrade Lifts Shares of Ameron (AMN) by ~9%
- Sterne Agee Upgrades TrustCo Bank Corp NY (TRST) to Neutral
- optionsXpress (OXPS) Upgraded Mid-Day at BofA, Stock Adds 3% to Today's Gains
- D.A. Davidson Upgrades Columbia Sportswear (COLM) to Buy
Lazard Capital upgrades Valeant Pharmaceuticals (NYSE: VRX) from Sell to Hold.
Valeant Pharmaceuticals International, a specialty pharmaceutical company, engages in the development, manufacture, and marketing of a range of pharmaceutical products.
Related Categories
UpgradesStocks Mentioned
+0.68Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
